J Liver Cancer.  2024 Mar;24(1):1-2. 10.17998/jlc.2024.02.13.

Radiofrequency for hepatocellular carcinoma larger than 3 cm: potential for applications in daily practice

Affiliations
  • 1Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea
  • 2Department of Internal Medicine, The Catholic University of Korea Uijeongbu St. Mary’s Hospital, Uijeongbu, Korea
  • 3Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Catholic University of Korea Seoul St. Mary’s Hospital, Seoul, Korea


Reference

References

1. Reig M, Forner A, Rimola J, Ferrer-Fàbrega J, Burrel M, Garcia-Criado Á, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022; 76:681–693.
Article
2. Cucchetti A, Piscaglia F, Cescon M, Colecchia A, Ercolani G, Bolondi L, et al. Cost-effectiveness of hepatic resection versus percutaneous radiofrequency ablation for early hepatocellular carcinoma. J Hepatol. 2013; 59:300–307.
Article
3. Ng KKC, Chok KSH, Chan ACY, Cheung TT, Wong TCL, Fung JYY, et al. Randomized clinical trial of hepatic resection versus radiofrequency ablation for early-stage hepatocellular carcinoma. Br J Surg. 2017; 104:1775–1784.
Article
4. Takayama T, Hasegawa K, Izumi N, Kudo M, Shimada M, Yamanaka N, et al. Surgery versus radiofrequency ablation for small hepatocellular carcinoma: a randomized controlled trial (SURF Trial). Liver Cancer. 2021; 11:209–218.
Article
5. Kariyama K, Nouso K, Hiraoka A, Toyoda H, Tada T, Tsuji K, et al. Treatment options for solitary hepatocellular carcinoma ≤5 cm: surgery vs ablation: a multicenter retrospective study. J Liver Cancer. 2023; Nov. 6. doi: 10.17998/jlc.2023.09.11. [Epub ahead of print].
Article
6. Yoon JH, Choi SK. Management of early-stage hepatocellular carcinoma: challenges and strategies for optimal outcomes. J Liver Cancer. 2023; 23:300–315.
Article
7. Korean Liver Cancer Association (KLCA); National Cancer Center (NCC) Korea. 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. Clin Mol Hepatol. 2022; 28:583–705.
8. Hasegawa K, Takemura N, Yamashita T, Watadani T, Kaibori M, Kubo S, et al. Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2021 version (5th JSH-HCC guidelines). Hepatol Res. 2023; 53:383–390.
Article
9. Shao YY, Wang SY, Lin SM; Diagnosis Group; Systemic Therapy Group. Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan. J Formos Med Assoc. 2021; 120:1051–1060.
Article
10. Okinaga H, Yasunaga H, Hasegawa K, Fushimi K, Kokudo N. Short-term outcomes following hepatectomy in elderly patients with hepatocellular carcinoma: an analysis of 10,805 septuagenarians and 2,381 octo- and nonagenarians in Japan. Liver Cancer. 2018; 7:55–64.
Article
Full Text Links
  • JLC
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr